Feasibility of energy-guided short duration protocol of laser balloon based pulmonary vein isolation for atrial fibrillation (EG-Laser Study).


Journal

Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944

Informations de publication

Date de publication:
07 2023
Historique:
revised: 30 05 2023
received: 30 07 2022
accepted: 03 06 2023
medline: 14 7 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: ppublish

Résumé

Laser balloon-based pulmonary vein isolation (LB-PVI) is available for atrial fibrillation (AF) ablation. The lesion size depends on laser energy; however, the default protocol is not an energy-based setting. We hypothesized that an energy-guided (EG) short-duration protocol may be an alternative to shorten the procedure time without affecting efficacy and safety. We evaluated the efficacy and safety of the EG short-duration protocol (EG group) (target energy 120 J/site [12W/10s; 10W/12s; 8.5W/14s; 5.5W/22s]) compared with the default protocol (control group) (12W/20s; 10W/20s; 8.5W/20s; 5.5W/30s). A total of 52 consecutive patients (EG: n = 27 [103veins] and control: n = 25 [91veins]) undergoing LB-PVI (64 ± 10 years, 81% male, 77% paroxysmal) were enrolled. The EG group had a shorter total time in the pulmonary vein (PV) (43.0 ± 13.9 min vs. 61.1 ± 16.0 min, p < .0001), a shorter total laser application time (1348 ± 254 sec vs. 2032 ± 424 sec, p < .0001), and lower total laser energy (12455 ± 2284J vs. 18084 ± 3746J, p < .0001). There was no difference in the total number of laser applications (p = 0269) or first-pass isolation (p = .725). Acute reconduction was identified only in one vein in the EG. No significant differences were observed in the incidence of pinhole rupture (7.4% vs. 4%, p = 1.000) or phrenic nerve palsy (3.7% vs. 12%, p = .341). During a mean follow-up of 13.5 ± 6.1 months, Kaplan-Meier analysis revealed no significant difference in atrial tachyarrhythmia recurrence (p = .227). LB-PVI with the EG short-duration protocol may be achieved in a shorter procedure time to avoid deterioration of efficacy and safety. The EG protocol is feasible as a novel point-by-point manual laser-application approach.

Sections du résumé

BACKGROUND
Laser balloon-based pulmonary vein isolation (LB-PVI) is available for atrial fibrillation (AF) ablation. The lesion size depends on laser energy; however, the default protocol is not an energy-based setting. We hypothesized that an energy-guided (EG) short-duration protocol may be an alternative to shorten the procedure time without affecting efficacy and safety.
METHODS
We evaluated the efficacy and safety of the EG short-duration protocol (EG group) (target energy 120 J/site [12W/10s; 10W/12s; 8.5W/14s; 5.5W/22s]) compared with the default protocol (control group) (12W/20s; 10W/20s; 8.5W/20s; 5.5W/30s).
RESULTS
A total of 52 consecutive patients (EG: n = 27 [103veins] and control: n = 25 [91veins]) undergoing LB-PVI (64 ± 10 years, 81% male, 77% paroxysmal) were enrolled. The EG group had a shorter total time in the pulmonary vein (PV) (43.0 ± 13.9 min vs. 61.1 ± 16.0 min, p < .0001), a shorter total laser application time (1348 ± 254 sec vs. 2032 ± 424 sec, p < .0001), and lower total laser energy (12455 ± 2284J vs. 18084 ± 3746J, p < .0001). There was no difference in the total number of laser applications (p = 0269) or first-pass isolation (p = .725). Acute reconduction was identified only in one vein in the EG. No significant differences were observed in the incidence of pinhole rupture (7.4% vs. 4%, p = 1.000) or phrenic nerve palsy (3.7% vs. 12%, p = .341). During a mean follow-up of 13.5 ± 6.1 months, Kaplan-Meier analysis revealed no significant difference in atrial tachyarrhythmia recurrence (p = .227).
CONCLUSION
LB-PVI with the EG short-duration protocol may be achieved in a shorter procedure time to avoid deterioration of efficacy and safety. The EG protocol is feasible as a novel point-by-point manual laser-application approach.

Identifiants

pubmed: 37334754
doi: 10.1111/pace.14760
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

607-614

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018;20:e1-e160.
Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016;374:2235-2245.
Dukkipati SR, Cuoco F, Kutinsky I, et al. Pulmonary vein isolation using the visually guided laser balloon: a prospective, multicenter, and randomized comparison to standard radiofrequency ablation. J Am Coll Cardiol 2015;66:1350-1360.
Metzner A, Wissner E, Schoonderwoerd B, et al. The influence of varying energy settings on efficacy and safety of endoscopic pulmonary vein isolation. Heart Rhythm 2012;9:1380-1385.
Bordignon S, Chun KRJ, Gunawardene M, et al. Energy titration strategies with the endoscopic ablation system: lessons from the high-dose vs. low-dose laser ablation study. Europace 2013;15:685-689.
Nagase T, Asano S, Yukino M, et al. Influence of various energy settings and overlap ratios on size and continuity of lesions in a laser balloon ablation in vitro model. J Cardiovasc Electrophysiol 2019;30:1330-1338.
Heeger CH, Tiemeyer CM, Phan HL, et al. Rapid pulmonary vein isolation utilizing the third-generation laserballoon - the PhoeniX registry. Int J Cardiol Heart Vasc 2020;29:100576.
Gao X, Chang D, Bilchick KC, et al. Left atrial thickness and acute thermal injury in patients undergoing ablation for atrial fibrillation: laser versus radiofrequency energies. J Cardiovasc Electrophysiol 2021;32:1259-1267.
Nagase T, Seki R, Asano S, et al. Evaluation of different ablation strategies verifying the optimal overlap ratio in point-by-point laser balloon ablation for patients with atrial fibrillation. Heart Rhythm O2 2021;2:347-354.
Schmidt B, Petru J, Chun KRJ, et al. Pivotal study of a novel motor-driven endoscopic ablation system. Circ Arrhythm Electrophysiol 2021;14:e009544.
Kondo Y, Kajiyama T, Nakano M, Kobayashi Y, High-power short-duration ablation with laser balloon. J Cardiovasc Electrophysiol 2019;30:1690-1691.
Heeger CH, Phan HL, Meyer-Saraei R, et al. Second-generation visually guided laser balloon ablation system for pulmonary vein isolation: learning curve, safety, and efficacy-the MERLIN registry. Circ J 2019;83:2443-2451.
Chun JKR, Bordignon S, Last J, et al. Cryoballoon versus laserballoon: insights from the first prospective randomized balloon trial in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2021;14:e009294.
Rovaris G, Ciconte G, Schiavone M, et al. Second-generation laser balloon ablation for the treatment of atrial fibrillation assessed by continuous rhythm monitoring: the LIGHT-AF study. Europace 2021;23:1380-1390.
Wei Y, Zhang N, Jin Q, et al. Comparison of efficacy and safety of laser balloon and cryoballoon ablation for atrial fibrillation-a meta-analysis. J Interv Card Electrophysiol 2019;54:237-245.
Tohoku S, Bordignon S, Chen S, et al. Validation of lesion durability following pulmonary vein isolation using the new third-generation laser balloon catheter in patients with recurrent atrial fibrillation. J Cardiol 2021;78:388-396.

Auteurs

Makoto Sano (M)

Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yoshihisa Naruse (Y)

Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yutaro Kaneko (Y)

Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Tomoaki Sakakibara (T)

Department of Cardiology, Iwata City Hospital, Iwata, Japan.

Taro Narumi (T)

Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Tsuyoshi Urushida (T)

Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yuichiro Maekawa (Y)

Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH